Physician profile
Mary Blomquist
NPI 1275597791
$1,060.96
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $266.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $255.55 | 2019-2020 | |
| Csl Behring | $153.19 | 2019 | |
| Grifols USA, LLC | $91.67 | 2019 | |
| Octapharma USA, INC. | $90.58 | 2019-2020 | |
| Genzyme Corporation | $82.60 | 2019-2020 | |
| Shire North American Group INC | $68.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $52.52 | 2019-2020 | |
| Glaxosmithkline, LLC. | $52.14 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.67 | 2020 | |
| Novartis Pharmaceuticals Corporation | $51.47 | 2019-2020 | |
| Alk-Abello, INC | $51.42 | 2019-2020 | |
| Optinose US, INC. | $24.87 | 2019-2020 | |
| Kaleo, INC. | $19.08 | 2019 | |
| Pfizer INC. | $15.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Blomquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.